The abstract 8550 posted in ASCO 2022 demonstrated that patients with tumoral PD-L1 expression of < 1% had a significantly lower survival probability, compared to those of 1–50% and > 50% in patients with stage III unresectable NSCLC who received durvalumab post cCRT [135]. Here, CD274 is linked to non-small cell lung carcinoma.